Scar-driven changes in joint tissue may underlie treatment resistance in rheumatoid arthritis, opening the door to new ...

Jersey City’s top-rated PT clinic celebrates a 15-year milestone of delivering personalized,non-surgical physical ...

"It's red light," Dr Cal Shields explains. "This is going to repair cells - not fry them. "Just 15 minutes," he says, as he ...

Hair loss is a common concern for many men, and it often affects confidence as well as appearance. In recent years, ...

A first-in-human clinical trial led by an international team of researchers and published in the New England Journal of ...

Catharina-Amalia, the future Queen of the Netherlands and her younger sister, Alexia, were the targets of a suspected ...

From PCR and CRISPR to autophagy and targeted cancer therapies, scientists share the discoveries that shaped their work and ...

The agency's decision was based on data from the VERITAC-2 trial, which showed Veppanu improved progression-free survival by nearly three months over fulvestrant.

In seven patients, there were no signs of toxicity with proton-beam radioablation, clearing the way for future studies.

A man who orchestrated a sophisticated cyberattack that crippled Auburn's town systems and targeted a local police detective ...

Arvinas said Friday the FDA approved the drug, known generically as vepdegestrant, to treat adults with certain forms of advanced metastatic breast cancer whose disease worsened following at least one ...

VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader –– Approval received in advance of ...